Posts Tagged ‘#smallcapstocks’
INTERVIEW: IntellaEquity $IEQ.ca Discusses Opportunistic Investments in the Industrial, AI and Blockchain Sectors
VIDEO: Good Life Networks $GOOD.ca CEO Jesse Dylan Discusses Recent Agreement with AMPD (Game Technology) CEO Anthony Brown $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca
Bougainville $BOG.ca Signs Binding LOI to Acquire Assets of Gene Bank Research Inc. $CROP.ca $VP.ca NF.ca $MCOA
- Entering the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc.,
- Places Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.
VANCOUVER, British Columbia, Nov. 01, 2018 — BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company“) (CSE:BOG) is pleased to announce that it has entered the Canadian cannabis market through the signing of a binding Letter of Intent to acquire the assets and inventory of Gene Bank Research Inc., placing Bougainville in a strong position to capitalize on the market opportunities created by the new Cannabis Act.
About Gene Bank Research Inc.
Gene Bank has over 110 lab-tested craft strains developed by its team of knowledgeable breeders possessing over 17 years’ experience. These unique craft strains allow licensed producers to stand out in an increasingly generic and homogenized market.
The Gene Bank assets include:
- Seeds – a collection of many of the building block genetics of today’s top ranked strains from around the world and used by top breeders
- Clones – the healthiest genetic selections based on specific phenotype/genotype characteristics
- Adult Plants – thousands of plants grown out to select the strongest, healthiest, highest yielding and disease/mold resistance available
- Graphed plants – unique super strains created by graphing the industry’s hardiest strains with weaker more finicky varieties
Principle LOI Terms
- Binding LOI
- Transfer of 100% of Gene Bank’s assets and current inventory to Bougainville
- Payment of $5,000,000 of Bougainville shares, with the price of such BOG shares to be based on 5 day volume weighted average price (“VWAPâ€) by reference to October 30, 2018
- Assets include:
- Seeds
- Genetic Lab Reports
- All Proprietary Information
- Bank Accounts
- Business Deck
- Corporation Documents
CEO, Andy Jagpal Comments:
“The acquisition of Gene Bank greatly expands our reach through vertical integration with the ability to provide unique and highly valued strains of seeds and clones to the cannabis market. I am confident this acquisition can substantially enhance Bougainville’s market value.”
About Bougainville Ventures, Inc.Â
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.
For more information please visit: http://bougainvilleinc.com/
On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.
Andy Jagpal, CEO and Director
For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420Â
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOGâ€); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.
A Social Network You Can Make a Living From #Peeks $PEEK.ca $IDK.ca $BCOV $AVID
Peeks Social has a social network that you can make a living from.
Peeks Social is a live-streaming social network which enables social and commercial interactions, Peer-to-Peer payments, and other social commerce capabilities. Peeks Social is the world’s first social network which bridges the gap between traditional social media and professionally produced content via live or pre-recorded broadcasts. Peeks Social enables content creators to immediately monetize their content through patented and proprietary payment technologies.
The Most Rewarding Live Streaming Platform
Go Live
Start broadcasting your stream from anywhere to anyone in the world.
Get Paid
Collect tips, get sponsored, use paywalls and get paid for your content.
Get Popular
Grow your followers overnight by getting featured in Peeks Social.
Explore
Watch exclusive live streams and videos from around the world and receive special offers.
For more information on Peeks Social Ltd. (PEEK:TSX.V) please fill out the form below.
Source: https://www.b-tv.com/peeks-social-company-feature-ep-332/
Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced that is has received a “No Objection Letter†(NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
- This represents the first ever human clinical trial featuring a vaporized cannabinoid drug productÂ
OTTAWA, Nov. 01, 2018 — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€) today announced that is has received a “No Objection Letter†(NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain.  It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.
“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,†said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor. This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need. It may also provide an alternative mode of delivery for those patients who prefer not to smoke.â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
| For further information, please contact Tetra Bio-Pharma Inc. | |
| Robert Bechard | |
| Executive Vice-President Corporate Development and Licensing | |
| 514-817-2514 | |
| [email protected] | |
| Media Contact | |
| energi PR | |
| Carol Levine | Stephanie Engel |
| 514-288-8500 ext. 226 | 416-425-9143 ext. 209 |
| [email protected] | [email protected] |
Tetra $TBP.ca Natural Health Signs Exclusive Agreement for the Distribution of their #Hemp Energy Drink in Canada and the USA $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink
- In the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products
OTTAWA, Nov. 01, 2018 – Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra†or the “Companyâ€) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,†stated Richard Giguere, CEO of Tetra Natural Health.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,†stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]
Stephanie Engel
416-425-9143 ext. 209
[email protected]
CLIENT FEATURE: Labrador Gold’s Shaw Ryan Targeting the Under Explored Gold Potential of the Province
-
- Led by Shawn Ryan, who’s prospecting and soil geochemistry work led to the discovery of White Gold, Coffee, and QV projects for a total of 7.5M ounces Au
- White Gold’s geochemical sampling program led to successful drill program
- Exploration has already outlined district scale soil anomalies on two projects in Labrador
- Hopedale property contains the Florence Lake greenstone belt and the Hunt River, both of which are under-explored for gold
- Florence Lake greenstone belt has a 40 KM strike length
- Â Ppreliminary soil geochemical results show arsenic anomalies in several areas
- Arsenic is a pathfinder element when exploring for gold
FULL DISCLOSURE: Labrador Gold is an advertising client of AGORA Internet Relations Corp.
VIDEO: Northbud $NBUD.ca October Construction Update $ACB $WEED.ca $HIP.ca
NORTHBUD October Construction Update. Everything is on schedule!
UpGrad acquires job skilling startup Acadview #India #edtech $BTRU.ca $ARCL $CPLA $BPI $FC.ca
UpGrad, promoted by entrepreneur Ronnie Screwvala, aims to extend its online learning platform to the undergraduate level through the Acadview acquisition
- Acadview marks Upgrad’s second acquisition in two years
- Recent transaction marks Upgrad’s second acquisition in two years. It is looking to capture a large chunk of the $20 billion education market in India
New Delhi: Online education startup UpGrad has acquired job skilling platform Acadview Software Pvt. Ltd for an undisclosed sum, UpGrad said in a statement on Monday. UpGrad, promoted by entrepreneur Ronnie Screwvala, aims to extend its online learning platform to the undergraduate level through the acquisition.
Founded in early 2015, Acadview seeks to upskill graduates with in-demand technologies through live online courses and industry projects, enabling better employment opportunities. It claims to have trained more than 3,000 students in 2017.
“UpGrad’s highly engaging online learning solution along with Acadview’s solid presence within the college space in India will allow us to deploy learning solution for college students at a massive scale,†said Screwvala and Mayank Kumar, co-founders at UpGrad, in a joint statement.
Gurugram-based Acadview had raised an undisclosed amount of funding from angel investors in India and the Silicon Valley. It has also partnered with over 80 universities and colleges in north India.
“Equipping students with engaging content, personalized coaching, hands-on experience with real world projects and guidance from subject matter experts in the industry can bring a step change in the quality of workforce available to employers.We believe in UpGrad’s vision, and feel that we have found a perfect cultural fit for our mission,†said Himanshu Batra, founder and chief executive at Acadview.
The recent transaction marks Upgrad’s second acquisition in two years. It is looking to capture a large chunk of the $20 billion education market in India.
Founded by Screwvala, Kumar, Phalgun Kompalli and Ravijot Chugh, UpGrad offers online courses in entrepreneurship, digital marketing and data analytics, among others, for working professionals.
UpGrad competes with foreign online education start-ups, including Coursera and Udacity, and home-grown ventures such as EduReka and Simplilearn.
Mint reported in October 2017 that UpGrad is also looking at to enter foreign markets in West Asia and South East Asia, and had committed ₹300 crore to fund the expansion. The corpus is three times the amount it had invested in the Indian market.
Source: https://www.livemint.com/Companies/If8GzLkcRMUwA5W0D0r1CL/UpGrad-acquires-job-skilling-startup-Acadview.html